Redox BiologyPharmacology & ToxicologyPeer-reviewed journal article
Inhibition of 3-mercaptopyruvate sulfurtransferase enhances CD8⁺ T-cell antitumor immunity
Muriel UrwyleriD, Marietta Margaréta KorsósiD, Eloïse DupuychaffrayiD, Nikita MarkoviD, Kelly AscençãoiD, Maria PetrosinoiD, Karim ZuhraiD, Darko StojkoviD, Sara Barcos, Jérémie TachetiD, Pragallabh Purwar, Montserrat Alvarez, Aurélien PommieriD, Mohamed Zakaria GadiD, Reham M. Abdel-Kader, Csaba SzabóiD, Carole BourquiniD
Abstract
Hydrogen sulfide (H2S) is a redox-active gasotransmitter implicated in tumor progression and immune regulation. The enzyme 3-mercaptopyruvate sulfurtransferase (3-MST) is a key contributor to endogenous H2S and polysulfide production, but its role in tumor-immune interactions remains poorly defined. Here, we show that 3-MST is the most abundantly expressed H2S-synthesizing enzyme in human renal cell carcinoma cells (RCC) and that high 3-MST expression correlates with reduced patient survival. Pharmacological inhibition of 3-MST lowered intracellular H2S levels in Renca renal carcinoma cells, suppressed proliferation, induced apoptosis, and increased surface expression of the immunogenic markers CD70, CD86, and PD-L1. In immune cells, partial inhibition of 3-MST promoted T cell activation, as evidenced by increased CD69 expression on both CD4 helper and CD8 cytotoxic T cells. In contrast, complete inhibition of 3-MST, achieved by high concentrations of the inhibitor, modestly reduced CD8 T cell proliferation. Functionally, 3-MST inhibition potentiated antigen-specific CD8 T cell-mediated killing of tumor cells, an effect further amplified by PD-L1 blockade. These results establish 3-MST as a redox-sensitive metabolic driver of tumor growth and immune evasion in RCC and demonstrate that its inhibition can boost antitumor immune responses, offering a potential avenue for combination immunotherapy.
- organism: human
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: cell signaling & trafficking
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 0th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Targeting 3-mercaptopyruvate sulfurtransferase induces cancer stem cell death
Kelly Ascenção, Olivia Oravecz, Csaba Szabó·bioRxiv·Mar 27, 2026
- Targeting PRMT3 Impairs Methylation and Oligomerization of HSP60 to Boost Anti-Tumor Immunity by Activating cGAS/STING Signaling
Yunxing Shi, Zongfeng Wu, … Binkui Li·Nature CommunicationsPeer-reviewed·Sep 10, 2024
- Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and rewires the microenvironment toward an immune-suppressive state
Y. Tang, D. J. Kwiatkowski, E. P. Henske·bioRxiv·Jun 1, 2022
- mTOR inhibition augments antitumor immune effector response by reprogramming the TP53-mutant, immune-cold HNSCC tumor microenvironment.
Priyatosh Nath, Alok R. Khandelwal, … Cherie‐Ann O. Nathan·NeoplasiaPeer-reviewed·Aug 8, 2026
- p38 blockade reverses the immune suppressive tumor microenvironment in metastatic breast cancer
Priyanka Rajan, Robert A. Zollo, … Andrei V. Bakin·bioRxiv·May 8, 2025
- Anti-PTHrP blockade limits CD8+ T-cell exhaustion in anti-cancer immunotherapy
Bastien Moës, Yunfeng Gao, … Christopher E. Rudd·bioRxiv·Oct 23, 2024